Sarah R DiNapoli

11PUBLICATIONS
38CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsInnate immunityMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 16, 2026
Lethal toxin-equipped effector cells for the potential treatment of cancer.

Alexander H Pearlman, Brian J Mog, Michael S Hwang

|Dec 22, 2025
TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers.

Jiaxin Ge, Joshua Urban, Sarah R DiNapoli

|Jul 10, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.

Brian J Mog, Nikita Marcou, Sarah R DiNapoli

|Aug 21, 2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.

Katharine M Wright, Sarah R DiNapoli, Michelle S Miller

|Sep 07, 2021
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.

Michael S Hwang, Michelle S Miller, Puchong Thirawatananond

|Mar 18, 2021
Targeting loss of heterozygosity for cancer-specific immunotherapy.

Michael S Hwang, Brian J Mog, Jacqueline Douglass

Pageof 2

Frequent Collaborators

9 joint publications

Maximilian F Konig

9 joint publications

Suman Paul

8 joint publications

Alexander H Pearlman

7 joint publications

Jacqueline Douglass